American College of Cardiology
Medicare beneficiaries who received an implantable pulmonary artery pressure (PAP) sensor had a statistically significant 45 percent lower rate of heart failure hospitalizations and reduced costs at six months, according to a retrospective cohort study.
Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.
On the final day of this year’s American College of Cardiology (ACC) conference, Mary Norine Walsh, MD, assumed her role as the president of the organization.
Findings presented at the American College of Cardiology’s 66th Annual Scientific Session show that adding a cholesterol-lowering drug to treatment with a statin has no effect on cognition and thinking.
New research looking at the efficacy of rivaroxaban, an oral blood-thinning medication compared to aspirin yielded positive results for the complex drug, showing that it can limit the recurrence of a venous thromboembolism (VTE) without increasing the risk for bleeding.
New results on Abbott Vascular’s Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were revealed at this year’s American College of Cardiology (ACC)’s Scientific Session, providing disappointing results for the stent that are consistent with a trend set by previous studies.
Subclinical leaflet thrombosis occurred in 13.6 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and 3.8 percent of patients undergoing surgical aortic valve replacement (SAVR), according to an analysis of two registries.
Research from the University of Louisville has found that the Abiomed Impella 2.5 heart pump helps reduce the risk of acute kidney injury—even in patients with preexisting kidney disease—when physicians are trying to complete a high-risk percutaneous coronary intervention (HRPCI).
A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.
At 12 months, patients with stable angina or acute coronary syndrome had similar rates of major adverse cardiac events whether they underwent revascularization guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to a randomized, registry-based trial.
A coalition of medical centers in southeast Michigan have found a way to increase the survival rate of cardiogenic shock patients to 84 percent by using a heart pump manufactured by Danvers, Massachusetts-based Abiomed. 
Patients with chronic total occlusions (CTOs) had similar results whether they underwent PCIs or received optimal medical treatment, according to a prospective, open-label, randomized trial.
Patients with hypertension who received an electronic counseling intervention had a 10.1 mmHg reduction in systolic blood pressure after a year compared with a six mmHg reduction for a control group, according to a randomized, double-blind controlled trial in Canada.
An analysis of two randomized trials found that taking bococizumab had no benefits with regards to reducing the risk of major adverse cardiovascular events in lower cardiovascular risk patients.
Inclisiran, a PCSK9 synthesis inhibitor designed to lower cholesterol levels in the blood, was shown to significantly lower low-density lipoprotein cholesterol (LDL-C) while maintaining standards of safety and tolerability for every single patient in a clinical trial, a triumph in treatment for cardiovascular disease caused by high cholesterol. 
After two years, intermediate-risk patients with severe symptomatic aortic stenosis had similar rates of all-cause mortality or disabling stroke whether they underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), according to a randomized trial.
Structural & Congenital Heart Disease
Mar 17, 2017 | Practice Management
Although patients with atherosclerotic cardiovascular disease and high levels of low-density lipoprotein (LDL) cholesterol benefited from receiving evolocumab plus statin therapy, the results of the randomized FOURIER trial did not impress Wall Street as shares of the drug’s manufacturer, Amgen, declined shortly after the findings were announced.
Practice Management
Mar 15, 2017 | Heart Failure
Though cannabis has increasingly been making its way into healthcare as a method for treating a series of conditions, new research on the drug, presented at the American College of Cardiology (ACC)’s Scientific Session beginning March 17, finds that it could cause severe cardiovascular events.
Heart Failure
Mar 09, 2017 | Heart Failure
While Zika is most closely linked to causing severe birth defects in babies born from mothers with the virus, new research that will be presented at the American College of Cardiology (ACC)’s 66th Annual Scientific Session beginning on March 17 provides evidence that the virus could have detrimental effects on the heart.
Heart Failure
Recently, the ACC released updated data from CathPCI, which showed that more than 90 percent of PCI-capable hospitals in the U.S. used the registry. Of those sites, 70 percent submit data for all diagnostic catheterization and PCI procedures.
Coronary Intervention & Surgery
Jan 02, 2017 | Practice Management
A survey of U.S. cardiologists found that women were nearly three times as likely as men to report they experienced some form of discrimination. Women were significantly more likely to report sex and parenting discrimination, while men were significantly more to report racial and religious discrimination.
Practice Management